Unicorn AIM VCT plc
Interim Management Statement
For the period from 31 March 2012 to 30 June 2012
Introduction
The Company has prepared this Interim Management Statement (IMS) in accordance
with the Disclosure and Transparency Rules of the UK Listing Authority. The IMS
covers the three month period ended 30 June 2012, together with relevant
information up to the date of publication.
Investment Objective
The objective of the Company is to provide Shareholders with an attractive
return from a diversified portfolio of investments, predominantly in the shares
of AIM quoted companies, by maximising the stream of dividend distributions to
Shareholders from the income and capital gains generated by the portfolio.
It is also the objective that the Company should continue to qualify as a
Venture Capital Trust, so that Shareholders benefit from the taxation
advantages that this brings. To achieve this at least 70% of the Company's
total assets are to be invested in qualifying investments of which 30% by value
must be in ordinary shares carrying no preferential rights to dividends or
return of capital and no rights to redemption.
Performance
UK equity indices registered declines in the three month period ended 30 June
2012. The FTSE All-Share Index (excluding investment trusts) was down 2.6% on a
total return basis, the FTSE AIM All-Share Index on a similar basis fell by
14.8%, whilst the Numis Smaller Companies Index declined by 5.6%.
The Company outperformed during the period with Net Asset Value (NAV)
increasing by 1.7%. NAV performance is calculated on a total return basis,
after adding back dividends paid. No dividends were paid in the period.
As at 30 June 2012, the unaudited NAV was 99.1 pence per share, compared to an
unaudited NAV of 97.4 pence per share as at 31 March 2012.
Material Transactions
There were a small number of material transactions during the period under
review.
In the Company's qualifying portfolio, partial disposals were made in Abcam and
Animalcare in order to maintain appropriate weightings following strong share
price performance.
The qualifying holding in Prologic was sold in full after a recommended cash
offer for the business was announced at the end of March 2012.
In the non-qualifying portfolio, a partial disposal was made in the Unicorn UK
Smaller Companies Fund.
Net proceeds from these disposals amounted to just under £1.2m and the
aggregate capital gain was £48,000.
There were no new investments and no other material transactions in the period
under review.
Top 10 Equity Holdings at 30 June 2012, as a percentage (%) of the Fund
Abcam 16.0%
Unicorn UK Smaller Companies Fund 7.8%
Tracsis 3.6%
Anpario 3.5%
Mears Group 3.5%
IDOX 3.5%
Mattioli Woods 3.0%
Unicorn Mastertrust Fund 3.0%
Surgical Innovations 2.9%
Animalcare Group 2.7%
Total 49.5%
Material Events
In the three month period ended 30 June 2012, a total of 87,149 Ordinary Shares
were purchased for cancellation at an average price of 66.0 pence per share.
After the period end, a further 124,075 shares were purchased for cancellation
at a price of 71 pence per share.
There were no other material events during the period under review.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.